Samuel Lagercrantz: ”Geoffrey Hintons farhågor”

”Ska vi få en så ljus framtid som möjligt där AI används på bästa sätt behövs både de som ser risker med den nya tekniken och de som ser sig som teknikoptimiste...

Life science trends 2025 – Part 1 obesity drugs

More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...

Security flaw in Swedish breast cancer screening software – woman passed away

A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 o...

Bioscience – Groundbreaking Research & Diagnostics: Stockholm

Non-destructive testing and assembly control

Assess complete assembly.

Large study: The benefits and risks of obesity medications

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

Kennedy stoppar bidrag till vaccinalliansen Gavi

USA kommer inte längre ge ekonomiskt stöd till Gavi förrän den globala vaccinalliansen ”återvunnit allmänhetens förtroende”. Det meddelar USA:s hälsominister Ro...

Tio life science-projekt får miljonanslag – ny utlysning öppnar

En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.

Try arivis for free

30-day free trial offers a number of benefits.

USA:s regering skrotar vaccinavtal med Moderna

Trumpadministrationen har avbrutit ett kontrakt som tilldelats Moderna för den sena utvecklingsfasen av ett fågelinfluensavaccin för människor, samt rätten att ...

She is CSL Behring's new Nordic General Manager

Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy

FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...

Svensk obesitaskandidat visade lovande resultat – ”Kan få stor betydelse”

Tabletten ska främja viktminskning utan att påverka aptit eller muskelmassa. Resultaten är lovande, enligt en klinisk fas I-studie från Karolinska institutet oc...

Meet us at Control 2025

Innovations that drive efficiency.

LINK Medical recruits Swedish CEO

The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.

Introduction of ZEISS Imaging Systems for Super-Resolution

Webinar recording about the ZEISS Lattice SIM technology.

Moderna develops mRNA vaccine against norovirus

A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

Mastering Urine Microscopy: Techniques for Accurate Disease Detection

Live Webinar on September 25, 2024.

AstraZeneca to use American AI platform for cancer trials

In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Cost-efficient development of laboratory devices

8 ways to optimise development costs and speed up processes